Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics Inc. (SRPT)
:SRPT
SRPT Analyst Ratings
Hold
6 Buy
11 Hold
4 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SRPT Stock 12 Month Forecast
Average Price Target
$21.06
▼(-5.14% Downside)
| Highest Price Target$45.00 | Average Price Target$21.06 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Mizuho Securities
$26
Buy
17.12%
Upside
Reiterated
12/11/25
Oppenheimer
$37
Buy
66.67%
Upside
Reiterated
12/10/25
Wedbush
$32
Buy
44.14%
Upside
Initiated
12/09/25
Wells Fargo
$45
Buy
102.70%
Upside
Reiterated
11/26/25
William Blair
―
Hold
―
Reiterated
11/25/25
Sarepta Therapeutics: Hold Rating Amid ENDEAVOR Progress and Short-term ChallengesWe view the FDA approval to initiate ENDEAVOR Cohort 8 as a constructive step toward addressing safety concerns that have limited Elevidys access for nonambulatory patients. The addition of sirolimus into the immunosuppression regimen is aligned with expert recommendations and preliminary supportive data presented at the World Muscle Society (WMS) and could provide a viable pathway to restoring the expanded label if successful. Positive results could enable Sarepta to pursue label reinstatement as early as 2027. However, more broadly we continue to view the stock’s near-term upside potential as limited given that the recent failure of the ESSENCE trial could put at risk of losing marketing authorization and a lack of clarity into Elevidys revenue guidance for the coming quarters.
Bernstein
$18→$20
Hold
-9.91%
Downside
Reiterated
11/25/25
Citi
$18.91→$8
Sell
-63.96%
Downside
Reiterated
11/24/25
Morgan Stanley
$20
Hold
-9.91%
Downside
Reiterated
11/24/25
Cautious Outlook on Sarepta Therapeutics Amid Early-Stage Trials and Financial CommitmentsWe view continued advancement of the DM1 trial as a positive, and interim data updates from the siRNA pipeline remain on track for 1Q26 (likely back half). 02:18 PM GMTM Update 2 M Inc (ARWR.O) We derive our PT from a Discounted Cash Flow (DCF) analysis that uses a discount rate of 10% and a terminal growth rate of 1%.
H.C. Wainwright
$5
Sell
-77.48%
Downside
Reiterated
11/17/25
Bank of America Securities
$18
Sell
-18.92%
Downside
Reiterated
11/14/25
Barclays
$22→$20
Hold
-9.91%
Downside
Reiterated
11/05/25
TD Cowen
$17
Hold
-23.42%
Downside
Reiterated
11/04/25
Evercore ISI
$17→$13
Hold
-41.44%
Downside
Reiterated
11/04/25
Needham
―
Sell
―
Reiterated
11/04/25
Robert W. Baird
$21→$15
Hold
-32.43%
Downside
Reiterated
11/04/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Mizuho Securities
$26
Buy
17.12%
Upside
Reiterated
12/11/25
Oppenheimer
$37
Buy
66.67%
Upside
Reiterated
12/10/25
Wedbush
$32
Buy
44.14%
Upside
Initiated
12/09/25
Wells Fargo
$45
Buy
102.70%
Upside
Reiterated
11/26/25
William Blair
―
Hold
―
Reiterated
11/25/25
Sarepta Therapeutics: Hold Rating Amid ENDEAVOR Progress and Short-term ChallengesWe view the FDA approval to initiate ENDEAVOR Cohort 8 as a constructive step toward addressing safety concerns that have limited Elevidys access for nonambulatory patients. The addition of sirolimus into the immunosuppression regimen is aligned with expert recommendations and preliminary supportive data presented at the World Muscle Society (WMS) and could provide a viable pathway to restoring the expanded label if successful. Positive results could enable Sarepta to pursue label reinstatement as early as 2027. However, more broadly we continue to view the stock’s near-term upside potential as limited given that the recent failure of the ESSENCE trial could put at risk of losing marketing authorization and a lack of clarity into Elevidys revenue guidance for the coming quarters.
Bernstein
$18→$20
Hold
-9.91%
Downside
Reiterated
11/25/25
Citi
$18.91→$8
Sell
-63.96%
Downside
Reiterated
11/24/25
Morgan Stanley
$20
Hold
-9.91%
Downside
Reiterated
11/24/25
Cautious Outlook on Sarepta Therapeutics Amid Early-Stage Trials and Financial CommitmentsWe view continued advancement of the DM1 trial as a positive, and interim data updates from the siRNA pipeline remain on track for 1Q26 (likely back half). 02:18 PM GMTM Update 2 M Inc (ARWR.O) We derive our PT from a Discounted Cash Flow (DCF) analysis that uses a discount rate of 10% and a terminal growth rate of 1%.
H.C. Wainwright
$5
Sell
-77.48%
Downside
Reiterated
11/17/25
Bank of America Securities
$18
Sell
-18.92%
Downside
Reiterated
11/14/25
Barclays
$22→$20
Hold
-9.91%
Downside
Reiterated
11/05/25
TD Cowen
$17
Hold
-23.42%
Downside
Reiterated
11/04/25
Evercore ISI
$17→$13
Hold
-41.44%
Downside
Reiterated
11/04/25
Needham
―
Sell
―
Reiterated
11/04/25
Robert W. Baird
$21→$15
Hold
-32.43%
Downside
Reiterated
11/04/25
Best Analysts Covering Sarepta Therapeutics
1 Month
xxx
Success Rate
24/38 ratings generated profit
Average Return
+7.19%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +7.19% per trade.
3 Months
xxx
Success Rate
11/18 ratings generated profit
Average Return
+3.92%
initiated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +3.92% per trade.
1 Year
2 Years
xxx
Success Rate
9/18 ratings generated profit
Average Return
+13.37%
initiated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +13.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SRPT Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
30
18
7
3
3
Buy
7
3
2
3
3
Hold
92
83
46
38
26
Sell
18
18
9
6
5
Strong Sell
8
7
5
5
5
total
155
129
69
55
42
Each month's total comprises the sum of three months' worth of ratings.
SRPT Financial Forecast
SRPT Stock Forecast FAQ
What is SRPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics Inc.’s 12-month average price target is 21.06.
What is SRPT’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for SRPT, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SRPT a Buy, Sell or Hold?
Sarepta Therapeutics Inc. has a consensus rating of Hold which is based on 6 buy ratings, 11 hold ratings and 4 sell ratings.
What is Sarepta Therapeutics Inc.’s price target?
The average price target for Sarepta Therapeutics Inc. is 21.06. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $5.00. The average price target represents -5.14% Decrease from the current price of $22.2.
The highest analyst price target is $45.00 ,the lowest forecast is $5.00. The average price target represents -5.14% Decrease from the current price of $22.2.
What do analysts say about Sarepta Therapeutics Inc.?
Sarepta Therapeutics Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 21 Wall Streets Analysts.
How can I buy shares of SRPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.